Prothrombin time: how blood clotting is assessed

Prothrombin time is a laboratory test that measures how many seconds it takes for blood plasma to form a clot after the addition of tissue factor, phospholipid, and calcium. Essentially, it evaluates the extrinsic and common coagulation pathways and is most sensitive to changes in factors II, V, VII, X, and fibrinogen. Therefore, this test has long been a basic hemostasis test. [1]

The result in seconds itself is useful, but it is poorly comparable between different laboratories because it is affected by reagents and thromboplastin sensitivity. It was to address this issue that the international normalized ratio was created. It is calculated from the patient's prothrombin time, the control value, and the thromboplastin sensitivity index, allowing for much better comparison of results between different systems when it comes to vitamin K antagonist therapy. [2]

In modern clinical practice, the main use of prothrombin time and international normalized ratio is related to the monitoring of warfarin and other vitamin K antagonists. Additionally, the test is used for unexplained bleeding, suspected vitamin K deficiency, liver disease, disseminated intravascular coagulation, and before certain interventions if an assessment of coagulation status is required. [3]

However, the test is almost never read alone. Modern sources emphasize that prothrombin time and international normalized ratio are usually interpreted in conjunction with activated partial thromboplastin time, clinical presentation, platelet count, fibrinogen, and medication information. An isolated number without context is often misleading. [4]

It's especially important not to turn this analysis into a universal "bleeding risk test." This is inappropriate, if only because the same value can mean different things in different conditions. The most telling example is liver cirrhosis: in such patients, the international normalized ratio reflects only a portion of the hemostatic changes and, by itself, does not provide a reliable assessment of the actual procedural risk of bleeding. [5]

Table 1. What does prothrombin time show?

Parameter	Practical significance
What is measured?	Plasma clotting time after addition of tissue factor and calcium
What links are assessed?	Extrinsic and common pathways of coagulation
To what factors is the test most sensitive?	Factors II, V, VII, X and fibrinogen
Why is it necessary to calculate the international normalized ratio?	To standardize results between laboratories during vitamin K antagonist therapy
Where analysis is particularly useful	Warfarin monitoring, evaluation of vitamin K deficiency, liver disease, bleeding and coagulopathy
What analysis cannot do	Independently and accurately predict the risk of bleeding in all clinical situations

The table is based on modern reviews, laboratory catalogues and materials on the standardization of the international normalized ratio. [6]

When is the test prescribed?

The most common indication is monitoring warfarin therapy. For this group of patients, the international normalized ratio remains the key parameter for safety and treatment efficacy. It is used by the physician to determine whether coagulation suppression is too weak, where the risk of thrombosis remains, or too strong, where the risk of bleeding increases. [7]

The second major group of indications is unexplained bleeding. If a patient experiences nosebleeds, bleeding gums, heavy menstrual periods, unexplained bruising, blood in the urine, or gastrointestinal bleeding, prothrombin time is part of the basic initial hemostasis assessment. In such situations, the test helps determine whether there is a disorder in the extrinsic or common coagulation pathway. [8]

The third area is liver disease. The liver synthesizes most coagulation factors, so severe dysfunction often prolongs prothrombin time. For this reason, the analysis is also used as part of the assessment of the liver's synthetic function, and the international normalized ratio is included in the calculation of a number of prognostic scores, including the end-stage liver disease score. [9]

The fourth situation is suspected vitamin K deficiency. Since vitamin K is necessary for the synthesis of factors II, VII, IX, and X, its deficiency leads to prolongation of prothrombin time. This can occur with insufficient dietary intake, fat malabsorption, cholestasis, prolonged use of antibiotics, and overdose of vitamin K antagonists. [10]

The fifth important group of indications is disseminated intravascular coagulation and other severe acquired coagulopathies. In these conditions, prothrombin time is often prolonged due to consumption of coagulation factors, but it is always assessed not in isolation, but in conjunction with fibrinogen, platelet count, D-dimer, and the clinical picture of severe disease. [11]

Table 2. When prothrombin time is prescribed

Clinical situation	Why is analysis needed?
Warfarin therapy	Selection and control of dose according to the international normalized ratio
Unexplained bleeding	Initial assessment of extrinsic and common coagulation pathway disorders
Suspected liver disease	Evaluation of the synthetic function of the liver
Possible vitamin K deficiency	Search for one of the reasons for prolongation of prothrombin time
Suspected disseminated intravascular coagulation	Coagulopathies assessment as part of an expanded panel
Preparation for individual interventions	Hemostasis testing in clinically indicated cases

The table is based on MedlinePlus, StatPearls, Mayo Clinic Laboratories, and ARUP Laboratories. [12]

How blood is drawn and why pre-analysis is critical

Blood collected in a sodium citrate test tube is used for analysis. A strict blood-to-anticoagulant ratio is crucial. If the tube is underfilled, the citrate concentration relative to plasma becomes too high, which can artificially prolong the results. Therefore, for coagulation tests, the quality of the blood sample is as important as the analysis itself. [13]

A high hematocrit is a separate issue. If the hematocrit exceeds 55%, the plasma fraction in a standard volume of blood decreases, and the relative citrate concentration increases. In this situation, the laboratory must reduce the volume of citrate in the test tube, otherwise the prothrombin time may appear falsely prolonged. This is a classic, yet often underestimated, cause of error. [14]

Sample delivery conditions are also important. Significant delays, improper storage temperatures, and gross violations of plasma preparation are undesirable for coagulation tests. Modern sources specifically warn that prothrombin time samples must be processed promptly, and with high-quality laboratory work, adherence to these conditions is essential for reliable results. [15]

The method of blood collection is also important. Samples from intravascular catheters can be contaminated with heparin or flushing solutions. This is especially dangerous if the interpretation is based on the collection route. In such situations, the extended test time is sometimes due not to the patient's illness, but to technical contamination of the sample. [16]

Finally, it's important to understand that the form may list both prothrombin time in seconds and the international normalized ratio (INR). For a patient not receiving vitamin K antagonists, the number of seconds itself and its comparison with the laboratory reference value is often more informative than the INR. For a patient on warfarin, on the contrary, the INR becomes the primary guideline for clinical decision-making. [17]

Table 3. What most often distorts the result

Factor	How the result changes
Underfilled test tube	Possible false extension
Hematocrit above 55% without citrate correction	Possible false extension
Long delay in delivery	Potential distortion of the result
Incorrect storage temperature	Possible distortion of coagulation factors
Collection from a catheter after heparin	Possible false extension
Incomparability of methods between different laboratories	Different results in one patient

The table is based on recommendations for working with coagulation samples and laboratory instructions of major reference laboratories. [18]

How to interpret the result

In people without anticoagulant therapy, the international normalized ratio is typically close to 1.0. Mayo Clinic data considers a value of up to 1.1 typical for people without significant pathology. However, there is no universal "normal value for everyone" for prothrombin time in seconds: laboratories use different thromboplastins and devices, so it is always necessary to look at the reference value of a specific form. [19]

If a patient is receiving warfarin, the focus is no longer on the "healthy range" but on the therapeutic range. For most indications, including atrial fibrillation and venous thromboembolism, an international normalized ratio of 2.0 to 3.0 is considered the target. The 2024 guidelines of the European Society of Cardiology specify this range for patients with atrial fibrillation prescribed a vitamin K antagonist. [20]

For mechanical valves, requirements may be more stringent. Current sources indicate that some patients require a higher target level, and the specific target depends on the valve type, its position, and the presence of additional thromboembolic risk factors. Therefore, the statement "2.0 to 3.0 is appropriate for everyone on warfarin" is incorrect. [21]

If the international normalized ratio is too high, the risk of bleeding increases. StatPearls indicates that values above 4.9 are considered critical. Warfarin management guidelines recommend temporarily discontinuing the vitamin K antagonist if the international normalized ratio is above 4.5 but below 10 and there is no clinically significant bleeding; values above 10 often require vitamin K, and sometimes more aggressive correction depending on the clinical situation. [22]

If the international normalized ratio (INR) consistently falls below the target range or fluctuates significantly, this is also a clinical concern. The 2024 atrial fibrillation guidelines state that in patients who cannot maintain an adequate time in the therapeutic range on vitamin K antagonists (i.e., less than 70%), if indicated and in the absence of contraindications, switching to a direct oral anticoagulant (DOC) should be considered. This further emphasizes that the INR is important, but even more important is its stability over time. [23]

Table 4. How to read the international normalized ratio in practice

Situation	The most typical interpretation
About 1.0 in a person without warfarin	Expected benchmark for most healthy people
2.0 to 3.0 on warfarin	Target range for many indications
Above target range on warfarin	Increasing risk of bleeding
Below target range on warfarin	Insufficient anticoagulation and risk of thrombosis
Higher target range in some patients with mechanical valves	The norm for a specific clinical indication, not an “overdose”
Normal value in a patient with suspected coagulopathy	Does not exclude pathology and requires evaluation of other tests

The table is based on StatPearls, Mayo Clinic, and the 2024 European Society of Cardiology guidelines. [24]

Causes of prolongation and shortening of prothrombin time

The most common cause of prolongation in outpatient practice is therapy with vitamin K antagonists. These drugs inhibit the synthesis of vitamin K-dependent factors II, VII, IX, and X, resulting in an increase in prothrombin time and an increase in the international normalized ratio. This mechanism underlies all laboratory monitoring of warfarin. [25]

The second major cause is vitamin K deficiency. It develops not only with poor nutrition, but also with impaired fat absorption, cholestasis, prolonged antibiotic use, and certain conditions following intestinal surgery. This deficiency is characterized by decreased synthesis of vitamin K-dependent factors and, as a result, prolonged prothrombin time. [26]

The third cause is liver disease. The liver synthesizes most coagulation factors, and with severe liver damage, their production decreases. But there's an important caveat: an elevated international normalized ratio in cirrhosis doesn't automatically mean a "high risk of bleeding in all situations," because natural anticoagulants are also reduced, and the hemostatic balance becomes more complex than a single test would indicate. [27]

The fourth cause is disseminated intravascular coagulation and severe consumptive coagulopathy. In these conditions, coagulation factors are consumed faster than they are replenished, resulting in prolonged prothrombin time. However, a definitive conclusion is never reached based on a single test: platelets, fibrinogen, D-dimer, and an assessment of the severity of the underlying disease are essential. [28]

Isolated shortening of prothrombin time is generally of less clinical value on its own. StatPearls notes that lower values are often associated with technical characteristics of the specimen, increased vitamin K intake, and conditions with higher fibrinogen and factor VII levels. Therefore, a "prothrombin time that is too short" is much less likely to lead to a significant diagnosis than a prolongation and often requires a review of technique and context first. [29]

Table 5. The most common causes of prolongation of prothrombin time

Cause	Mechanism
Warfarin and other vitamin K antagonists	Decreased synthesis of factors II, VII, IX and X
Vitamin K deficiency	Insufficient synthesis of vitamin K-dependent factors
Liver disease	Decreased synthetic function of the liver
Disseminated intravascular coagulation	Consumption of clotting factors
Deficiency of factors II, V, VII, X or fibrinogen	Disorders of the extrinsic and common coagulation pathways
Factor inhibitors	Functional inhibition of coagulation
Pre-analytical error	False prolongation without true coagulopathy

The table is based on StatPearls and Mayo Clinic Laboratories. [30]

Special clinical situations

The first and most important special situation is warfarin. For this case, the international normalized ratio is standardized and truly applicable for dosing. This is a case where the test isn't simply "helpful" but actually serves as a central tool in patient management. This is why the international normalized ratio still retains significant clinical value, despite the widespread use of direct oral anticoagulants. [31]

The second situation is direct oral anticoagulants. They can affect prothrombin time and sometimes prolong it, but conventional coagulation tests, including the international normalized ratio, are not sensitive or reliable enough to accurately determine clinically relevant levels of these drugs. Therefore, the international normalized ratio should not be used as a standard monitoring tool for apixaban, rivaroxaban, edoxaban, or dabigatran. [32]

The third situation is liver cirrhosis. In hepatology, the international normalized ratio is important as an indicator of liver synthetic function and a component of prognostic models, but this does not equate to its usefulness for predicting preprocedural bleeding. The American Association for the Study of Liver Diseases explicitly emphasizes that the international normalized ratio alone in cirrhosis is not a good measure of procedural bleeding risk, and prophylactic correction with plasma is generally not recommended. [33]

The fourth situation is preoperative assessment. Before interventions, prothrombin time is useful when there are clinical grounds to expect coagulopathy: warfarin therapy, suspected liver disease, a history of significant bleeding, malabsorption, or severe systemic disease. However, the pre-procedure test must be interpreted in the context of the entire patient, not as an automatic "clearance" or "non-clearance" for the procedure. [34]

The fifth situation involves patients with mechanical valves and certain high-thrombotic-risk groups. Here, the international normalized ratio remains a key guideline for long-term anticoagulation, and target ranges may be higher than for patients with atrial fibrillation or venous thromboembolism. For this category, attempting to simplify management to a general rule of "everyone needs 2.0 to 3.0" is dangerous. [35]

Table 6. Special clinical scenarios

Scenario	How to interpret the analysis correctly
Warfarin therapy	The International Normalized Ratio is the main instrument of control
Direct oral anticoagulants	The international normalized ratio is not suitable for routine monitoring.
Cirrhosis	Important for assessing synthetic function but does not provide a reliable assessment of procedural bleeding risk by itself
Preparing for the intervention	The analysis is useful only in a clinical context and not as the sole criterion for decision making.
Mechanical valves	The target range may be higher than usual.
Unstable international normalized ratio on vitamin K antagonists	It is necessary to look for the reasons for hesitation and reconsider tactics.

The table is based on StatPearls, the 2024 European Society of Cardiology guidelines, the American Association for the Study of Liver Diseases guidelines, and a review of direct oral anticoagulants. [36]

Limitations of the method and typical errors

The first common mistake is to assume that a prolonged prothrombin time always indicates a high risk of bleeding. This is incorrect because the causes of prolongation vary: warfarin, vitamin K deficiency, cirrhosis, disseminated intravascular coagulation, factor inhibitors, and laboratory error. The test itself does not automatically distinguish between these causes. [37]

The second mistake is confusing prothrombin time in seconds with the international normalized ratio. Seconds reflect the actual result on a specific system, while the international normalized ratio is a mathematically standardized derivative value, created primarily for vitamin K antagonists. The logic of the international normalized ratio cannot be mechanically transferred to all other clinical tasks. [38]

The third mistake is attempting to evaluate direct oral anticoagulants using the international normalized ratio. Although some of these drugs can alter prothrombin time, conventional tests are not suitable for reliably quantifying their effect. A particularly dangerous false sense of security is the misinterpretation of a "near-normal" international normalized ratio as a lack of anticoagulant effect. [39]

The fourth mistake is to perceive the international normalized ratio (INR) in cirrhosis as a direct indicator of procedural risk. Modern hepatology has long since abandoned this simplification. In cirrhosis, hemostasis is more complexly restructured than a single analysis suggests, and prophylactic correction based solely on the INR may be not only useless but also undesirable. [40]

The fifth mistake is ignoring the pre-analytical step. An underfilled tube, a high hematocrit without citrate correction, heparin contamination, and delayed processing can completely ruin the clinical value of the result. Therefore, when an unexpected deviation occurs, a competent approach often begins not with an immediate diagnosis, but with a quality control check of the sample and a repeat test. [41]

Frequently Asked Questions

What is the difference between prothrombin time and international normalized ratio?

Prothrombin time is the raw result in seconds obtained in a specific laboratory. The international normalized ratio is a standardized derivative value calculated from prothrombin time, taking into account the sensitivity of thromboplastin. For warfarin monitoring, it is the international normalized ratio that is usually of clinical importance. [42]

What value is considered normal?

For a person without anticoagulant therapy, the international normalized ratio is usually close to 1.0, and in many healthy people it is up to 1.1. However, for prothrombin time in seconds, one should only rely on the reference value of a specific laboratory, because different reagents give different absolute numbers. [43]

Does a high result always mean liver disease?

No. Prolongation is possible with warfarin, vitamin K deficiency, disseminated intravascular coagulation, coagulation factor deficiency, and a number of other causes. Liver disease is an important, but not the only cause. [44]

Can apixaban or rivaroxaban be monitored using the international normalized ratio?

No, it is not routinely possible. Direct oral anticoagulants may alter routine coagulation tests, but the international normalized ratio is not a reliable tool for monitoring them. [45]

Why does the international normalized ratio in cirrhosis not equal the risk of bleeding?

Because in cirrhosis, not only procoagulant proteins but also anticoagulant proteins are reduced. As a result, hemostasis in such patients undergoes complex restructuring, and the international normalized ratio alone does not reflect the entire balance. [46]

What are the international normalized ratio targets for warfarin?

For many indications, including atrial fibrillation and venous thromboembolism, the target range is 2.0 to 3.0. However, for some patients with mechanical valves, the targets are higher and are determined by the treating physician based on the specific clinical situation. [47]

What if the international normalized ratio is too high?

This depends on the level, the presence of bleeding, and the overall risk. For moderate elevations without bleeding, warfarin is often temporarily discontinued and monitoring is repeated. For values above 10, vitamin K is usually considered, and in the case of bleeding, more urgent and aggressive correction is required. Do not change your treatment on your own without consulting a doctor. [48]

Can a blood sampling error change the result?

Yes, and quite significantly. An underfilled tube, a high hematocrit without citrate correction, contamination of the sample with heparin, and delayed delivery can all produce false results. [49]

Conclusion

Prothrombin time is one of the basic hemostasis tests, but its strength lies not in its versatility but in its proper application. It is particularly important for monitoring vitamin K antagonist therapy, assessing vitamin K deficiency, liver disease, and coagulopathies of the extrinsic and common coagulation pathways. However, it should always be interpreted in the context of the clinical picture, other laboratory tests, and sample quality. [50]

The modern approach to this test is much more cautious than the older, simplified approaches. The international normalized ratio cannot be automatically applied to direct oral anticoagulants, and in cirrhosis, it cannot be considered a direct equivalent to procedural bleeding risk. It is precisely this contextual and evidence-based understanding that makes this article truly contemporary. [51]